Evidence map›Paper›PMID 42078894›Full record

ArticleResearch square2026

An adipocyte-endothelial framework to identify molecular signatures of metabolic vulnerability in obesity.

Vaishali Chaurasiya, Luyang Li, Aina Lluch, Ana Fernández-Sánchez, Jukka Harju, Dan Duc Pham, Sanni Perttunen, Salla Keskitalo, Markku Varjosalo, Kirsi H Pietiläinen and 25 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Vaishali ChaurasiyaMinerva Foundation Institute for Medical Research, and Doctoral Programme in Clinical Research, University of Helsinki - Helsinki, Finland.
Luyang LiDivision of Infection and Immunity, School of Medicine, and Systems Immunity Research Institute, Cardiff University - Cardiff, United Kingdom.
Aina LluchGirona Biomedical Research Institute (IDIBGI), and CIBER de la Fisiología de la Obesidad y la Nutrición (CIBEROBN) - Girona, Spain.
Ana Fernández-SánchezGirona Biomedical Research Institute (IDIBGI) - Girona, Spain.
Jukka HarjuDepartment of Gastrointestinal Surgery, Abdominal Center, University of Helsinki and Helsinki University Hospital - Helsinki, Finland.
Dan Duc PhamMinerva Foundation Institute for Medical Research - Helsinki, Finland.
Sanni PerttunenMinerva Foundation Institute for Medical Research - Helsinki, Finland.
Salla KeskitaloMolecular Systems Biology Research Group & Proteomics Unit, HiLIFE Helsinki Institute of Life Science, Institute of Biotechnology, University of Helsinki - Helsinki, Finland.
Markku VarjosaloMolecular Systems Biology Research Group & Proteomics Unit, HiLIFE Helsinki Institute of Life Science, Institute of Biotechnology, University of Helsinki - Helsinki, Finland.ORCID https://orcid.org/0000-0002-1340-9732
Kirsi H PietiläinenObesity Research Unit, Research Program for Clinical and Molecular Metabolism, and HealthyWeightHub, Endocrinology, Abdominal Center, Helsinki University Hospital, University of Helsinki - Helsinki, Finland.
P A Nidhina HaridasMinerva Foundation Institute for Medical Research - Helsinki, Finland.
José-Maria Moreno-NavarreteGirona Biomedical Research Institute (IDIBGI), CIBER de la Fisiología de la Obesidad y la Nutrición (CIBEROBN), and School of Medicine, University of Girona - Girona, Spain.
José I Rodríguez-HermosaGirona Biomedical Research Institute (IDIBGI), and School of Medicine, University of Girona - Girona, Spain.
Encarna Piedrafita-SerraGirona Biomedical Research Institute (IDIBGI), and School of Medicine, University of Girona - Girona, Spain.
Asha KarBioinformatics Interdepartmental Program, and Institute for Precision Health, David Geffen School of Medicine, UCLA - Los Angeles, USA.
Päivi PajukantaBioinformatics Interdepartmental Program, and Institute for Precision Health, David Geffen School of Medicine at UCLA - Los Angeles, USA.
Markku LaaksoInstitute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital - Kuopio, Finland.
Ville MännistöInstitute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital - Kuopio, Finland.
Jussi PihlajamäkiInstitute of Public Health and Clinical Nutrition, University of Eastern Finland and Kuopio University Hospital - Kuopio, Finland.
Minna U KaikkonenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland - Kuopio, Finland.
Gema FrühbeckInstituto de Investigación Sanitaria de Navarra (IdISNA), Clínica Universidad de Navarra, and CIBER de la Fisiología de la Obesidad y la Nutrición - Pamplona, Spain.ORCID https://orcid.org/0000-0002-8305-7154
Oriol A Rangel-ZúñigaMaimónides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, and CIBER de la Fisiología de la Obesidad y la Nutrición - Córdoba, Spain.
Francisco José TinahonesInstituto de Investigación Biomédica de Málaga (IBIMA), Virgen de la Victoria Hospital, University of Málaga, and CIBER de la Fisiología de la Obesidad y la Nutrición - Málaga, Spain.
Carlos DieguezCenter for Research in Molecular Medicine and Chronic Diseases (CiMUS, University of Santiago de Compostela, Instituto de Investigación Sanitaria, CIBER de la Fisiología de la Obesidad y la Nutrición - Santiago de Compostela, Spain.
Ralph BurkhardtInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg - Regensburg, Germany.
Marcus HöringInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg - Regensburg, Germany.
Gerhard LiebischInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg - Regensburg, Germany.
Johanna PörschkeInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Marburg University - Marburg, Germany.
María Gómez-SerranoInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Marburg University - Marburg, Germany.
Johannes GraumannInstitute of Translational Proteomics & Core Facility, Marburg University - Marburg, Germany.
Witold SzymanskiInstitute of Translational Proteomics & Core Facility, Marburg University - Marburg, Germany.
José-Manuel Fernández-RealGirona Biomedical Research Institute (IDIBGI), CIBER de la Fisiología de la Obesidad y la Nutrición (CIBEROBN), and School of Medicine, University of Girona - Girona, Spain.
You ZhouDivision of Infection and Immunity, School of Medicine, and Systems Immunity Research Institute, Cardiff University - Cardiff, United Kingdom.
Vesa OlkkonenMinerva Foundation Institute for Medical Research, and Department of Anatomy, Faculty of Medicine, University of Helsinki - Helsinki, Finland.
Francisco OrtegaGirona Biomedical Research Institute (IDIBGI), and CIBER de la Fisiología de la Obesidad y la Nutrición (CIBEROBN) - Girona, Spain.

Funding

Multimodal omics approach to identify health to cardiometabolic disease transitionsR01HL170604 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Paivi Pajukanta · 2023 to 2026
$2.8M
NHLBI NIH HHS R01 HL170604
6 · The paper itself

Abstract

Obesity-related metabolic disease is linked to impaired adipose tissue function, but the underlying molecular programs are difficult to assign to specific adipose-resident cell types, to mechanistically connect to inflammation, and to distinguish from alterations that normalize with weight loss. We integrated here a layered design combining untargeted proteomics and lipidomics to define obesity-associated, cell-type-resolved molecular phenotypes across isolated adipocytes and adipose microvascular endothelial cells, explore whether an obesity-like inflammatory milieu reproduces adipose-resident cell dysfunction, and identify molecular features that show evidence of recovery after surgery-induced weight loss. As expected, adipocytes from people with obesity show suppression of mitochondrial energy metabolism together with impaired lipid plasticity, as reflected by triglyceride remodelling. By mimicking an obesity-like inflammatory milieu with macrophage-conditioned media, we reproduced most of these changes in adipocyte cultures. Endothelial cells exhibited yet another, opposite trajectory in obesity, with reduced cell-cycle signalling and increased mitochondrial activation, which were recapitulated in vitro when these cells were exposed, respectively, to the secretions of inflamed macrophages and adipocytes. Bulk adipose tissue proteomes and lipidomes showed evidence of metabolic improvement after weight loss, with broad restoration of mitochondrial and substrate-handling pathways and reciprocal triglyceride remodelling. Alongside the inflammation-responsive adipocyte mitochondrial and lipid-handling dysfunction, our cell-type-informed framework probes macrophage and adipocyte-to-endothelial activation in obesity and delineates cross-context cellular programs that recover with weight loss. Additionally, we identified the elements that exhibit the strongest association with dyslipidaemia, hypertriglyceridemia and hyperglycaemia in individuals with obesity, confirming molecular signatures relevant to metabolic obesity in two cross-sectional samples.

Indexed as

adipocyteAdipose tissueendothelial celllipidomicsmeta-inflammationobesityproteomicsweight loss

Identifiers

PMID42078894
PMCPMC13131895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.